MedTrace Logo

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

NCT03482102 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-05-04

No results posted yet for this study

Summary

This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer.

The interventions involved in this study are:

* Durvalumab
* Tremelimumab
* Radiation Therapy

Conditions

Interventions

DRUG

Durvalumab

Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system

RADIATION

Radiation

Radiation therapy is used to shrink cancer cells.

DRUG

Tremelimumab

Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system

Sponsors & Collaborators

Principal Investigators

  • Julie Koenig, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2024-02-28
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03482102 on ClinicalTrials.gov